Pharmaceutical Articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Teens whose mothers had gestational diabetes are at greater risk of type 2 diabetes

Posted: September 1, 2014

Obese teenagers whose mothers had gestational diabetes while pregnant with them are at greater risk of developing Type 2 diabetes, a new study shows.

Fifteen injuries linked to defective jaw implant; device has been recalled

Posted: September 1, 2014

Certain implants used in adults, children and infants to lengthen and stabilize the lower jawbone or side jaw to correct birth defects or post-traumatic defects are being recalled because the device may reverse direction. To date, this device defect has

Drug companies race for FDA approval on new class of cholesterol lowering drugs

Posted: September 1, 2014

Pharmaceutical companies are in a desperate race to get their new type of cholesterol-lowering treatment reviewed and approved by drug regulators so they can be the first to hit the market and take a bite out of the multibillion-dollar statin

Antipsychotic drugs linked to kidney injury in elderly patients

Posted: August 31, 2014

Antipsychotic medications, including risperidone, can cause kidney injury, especially in elderly patients, according to a new study published in the Annals of Internal Medicine.

New testosterone treatment in development carries fewer side effects

Posted: August 31, 2014

Testosterone levels in men typically drop as a man ages, but when it drops too low it signals a possible problem. In many cases the drop can be associated with obesity, diabetes and circulatory disease.

Combining old diabetes drug with new improves blood sugar control

Posted: August 31, 2014

Combining the commonly used metformin with another class of medication can greatly improve blood sugar control in Type 2 diabetics, according to new research.

Young, African-American dialysis patients at greater risk of dying

Posted: August 30, 2014

Young African-Americans on dialysis are 1.5 times more likely to die than white dialysis patients, according to a study published in the Journal of the American Society of Nephrology.

Hundreds of Risperdal gynecomastia lawsuits filed in Philadelphia court

Posted: August 29, 2014

About 700 product liability lawsuits involving the antipsychotic Risperdal have been filed in Philadelphia Court of Common Pleas alleging use of the drug caused boys and young men to develop breasts, a condition referred to as gynecomastia. Many of the

Drug company testing type 2 diabetes drug designed to have fewer side effects

Posted: August 29, 2014

Drug developer BioKier currently testing a new oral formulation of type 2 diabetes treatment that may prove safer than injectable versions of the drug currently on the market.

Regeneron, Sanofi pay $67.5 million to expedite approval of experimental cholesterol drug

Posted: August 29, 2014

Regeneron Pharmaceuticals and Sanofi are paying $67.5 million to improve the chances of getting their experimental cholesterol-lowering drug on the market before any other drug company with similar cholesterol treatments in development. Regeneron and Sanofi are purchasing a first-of-its-kind voucher